文献速递泌尿男性生殖肿瘤

转移性去势敏感性前列腺癌转移时机的转录组与临床异质性

Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.
PubMed 文献 · Ann Oncol · 2023-05-08

这项国际多中心回顾性研究对252例完成原发肿瘤RNA表达谱检测的转移性去势敏感性前列腺癌(mCSPC)患者按同时性/异时性转移分层,比较转录组差异。同时性转移者5年OS更差(39%对79%),AR活性与雄激素反应标志物评分更低;仅高瘤负荷与雄激素反应标志物评分与OS独立相关。同时性转移者接受AR联合非AR联合治疗较单药OS更优,异时性者无此差异(交互P=0.05)。

要点

  • 同时性转移者5年OS为39%,异时性者为79%(P<0.01)。
  • 同时性转移者中位AR活性11.78、HAR评分3.15,分别低于异时性者的12.64、3.32(均P<0.01)。
  • 多因素Cox仅高瘤负荷(HR=4.97)与HAR评分(HR=0.51)与OS显著相关。

核心结论

  • mCSPC转移时机可能存在生物学差异:低瘤负荷异时性者转录谱更依赖激素且预后优于同时性低瘤负荷者。

研究设计与样本

  • 国际多中心回顾性研究,纳入252例完成原发肿瘤RNA表达谱检测的mCSPC男性患者,按同时性与异时性转移分层,中位随访39.6个月。

主要发现

  • 同时性转移者5年OS为39%,异时性者为79%(P<0.01)。
  • 同时性转移者中位AR活性为11.78,异时性者为12.64(P<0.01);同时性者HAR评分为3.15,异时性者为3.32(P<0.01)。
  • 多因素Cox回归中,仅高瘤负荷(HR=4.97,95%CI 2.71-9.10;P<0.01)与HAR评分(HR=0.51,95%CI 0.28-0.88;P=0.02)与OS显著相关。
  • 同时性转移者接受AR联合非AR联合治疗较单药OS更优(HR=0.47,95%CI 0.30-0.72;P<0.01),异时性者无此差异(HR=1.37,95%CI 0.50-3.92;P=0.56),交互P=0.05。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic castration-sensitive prostate cancer (mCSPC) is commonly classified into high- and low-volume subgroups which have demonstrated differential biology, prognosis, and response to therapy. Timing of metastasis has similarly demonstrated differences in clinical outcomes; however, less is known about any underlying biologic differences between these disease states. Herein, we aim to compare transcriptomic differences between synchronous and metachronous mCSPC and identify any differential responses to therapy. PATIENTS AND METHODS: We performed an international multi-institutional retrospective review of men with mCSPC who completed RNA expression profiling evaluation of their primary tumor. Patients were stratified according to disease timing (synchronous versus metachronous). The primary endpoint was to identify differences in transcriptomic profiles between disease timing. The median transcriptomic scores between groups were compared with the Mann-Whitney U test. Secondary analyses included determining clinical and transcriptomic variables associated with overall survival (OS) from the time of metastasis. Survival analysis was carried out with the Kaplan-Meier method and multivariable Cox regression. RESULTS: A total of 252 patients were included with a median follow-up of 39.6 months. Patients with synchronous disease experienced worse 5-year OS (39% versus 79%; P < 0.01) and demonstrated lower median androgen receptor (AR) activity (11.78 versus 12.64; P < 0.01) and hallmark androgen response (HAR; 3.15 versus 3.32; P < 0.01). Multivariable Cox regression identified only high-volume disease [hazard ratio (HR) = 4.97, 95% confidence interval (CI) 2.71-9.10; P < 0.01] and HAR score (HR = 0.51, 95% CI 0.28-0.88; P = 0.02) significantly associated with OS. Finally, patients with synchronous (HR = 0.47, 95% CI 0.30-0.72; P < 0.01) but not metachronous (HR = 1.37, 95% CI 0.50-3.92; P = 0.56) disease were found to have better OS with AR and non-AR combination therapy as compared with monotherapy (P value for interaction = 0.05). CONCLUSIONS: We have demonstrated a potential biologic difference between metastatic timing of mCSPC. Specifically, for patients with low-volume disease, those with metachronous low-volume disease have a more hormone-dependent transcriptional profile and exhibit a better prognosis than synchronous low-volume disease.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Sutera PA, Shetty AC, Hakansson A, et al. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Ann Oncol. 2023. PMID: 37164128. doi:10.1016/j.annonc.2023.04.515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。